Drew Moghanaki/X
May 18, 2025, 10:14
Drew Moghanaki: HORIZON-01 – ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib
Drew Moghanaki, Chief Medical Officer at Respirati, posted on X:
“Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib.
Thanks Millie Das for the heads up.”
Other posts featuring Drew Moghanaki on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49